edotreotide has been researched along with Cancer of Gastrointestinal Tract in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertagna, F; Bettinsoli, G; Biasiotto, G; Bosio, G; Dognini, L; Ferrari, C; Ferrari, V; Franco, F; Giubbini, R; Migliorati, E; Minari, C; Rodella, C; Savelli, G; Tomassetti, P; Zaniboni, A | 1 |
| Castaldi, P; Giordano, A; Rindi, G; Rufini, V; Treglia, G | 1 |
| Antoch, G; Binse, I; Bockisch, A; Boy, C; Brandau, W; Lahner, H; Petersenn, S; Poeppel, TD; Schott, M | 1 |
| Barone, R; Borson-Chazot, F; Chauvin, F; Gogou, L; Jamar, F; Krenning, EP; Kvols, LK; Pauwels, S; Valkema, R; Walrand, S | 1 |
| Angelini, C; Caprotti, R; Crippa, S; Mussi, C; Sartori, P; Uggeri, F | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
1 review(s) available for edotreotide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
Topics: Algorithms; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, Somatostatin; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, X-Ray Computed | 2012 |
3 trial(s) available for edotreotide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Retreatment; Survival Rate; Yttrium Radioisotopes | 2012 |
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Topics: Adult; Aged; Algorithms; Body Burden; Dose-Response Relationship, Radiation; Female; Gastrointestinal Neoplasms; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Pancreatic Neoplasms; Radiation Injuries; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome | 2005 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
2 other study(ies) available for edotreotide and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Topics: Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Gastrointestinal Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Octreotide; Palliative Care; Radiopharmaceuticals; Yttrium | 2005 |